June 21, 2021 07:14 AM EDT
R&D

No­var­tis bur­nish­es Zol­gens­ma da­ta in presymp­to­matic pa­tients as Roche's Evrys­di con­tin­ues eat­ing away at the SMA pie

Max Gelman

Senior Editor

With sales slow­ing and Roche’s Evrys­di hot on its tail, No­var­tis’ Zol­gens­ma for spinal mus­cu­lar at­ro­phy is seek­ing to build a sta­ble of da­ta in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times